C07K 2317/12
Isolated from milk
Official title: isolated from milk
C07K2317/12 (Isolated from milk) appears on 53 US grants and 117 published applications in this corpus.
Search patents in C07K- Granted patents
- 53
- Published applications
- 117
- Assignees
- 51
- Inventors
- 163
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 2 |
| 2003 | 0 | 2 |
| 2004 | 0 | 2 |
| 2005 | 1 | 5 |
| 2006 | 2 | 4 |
| 2007 | 1 | 5 |
| 2008 | 6 | 7 |
| 2009 | 3 | 5 |
| 2010 | 5 | 10 |
| 2011 | 5 | 2 |
| 2012 | 4 | 7 |
| 2013 | 4 | 10 |
| 2014 | 3 | 4 |
| 2015 | 1 | 6 |
| 2016 | 1 | 5 |
| 2017 | 1 | 5 |
| 2018 | 3 | 7 |
| 2019 | 4 | 6 |
| 2020 | 1 | 7 |
| 2021 | 4 | 5 |
| 2022 | 0 | 3 |
| 2023 | 1 | 2 |
| 2024 | 0 | 2 |
| 2025 | 1 | 2 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Composition and methods for preventing and treating African swine fever in wild and domestic swine14 Jan 2025US 12,194,096 B2Stevens Law Group
- Antibody purification4 Apr 2023US 11,618,769 B2
- Afucosylated monoclonal antibody9 Nov 2021US 11,168,143 B2Beijing Gefucure Biotechnology Limited Company
- Stable pooled breastmilk antibodies for oral delivery21 Sep 2021US 11,124,560 B2Lactiga, Inc.
- Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses23 Jul 2026US 2026/0209380 A1Janssen Biotech, Inc.
- Compositions and methods for treating gluten-related disorders8 Jan 2026US 2026/0007699 A1
- Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine10 Jul 2025US 2025/0222101 A1Mammal Labs Inc.
- Treatment of staphylococcus related diseases26 Jun 2025US 2025/0206810 A1Doderm GmbH
- Bovine colostrum derived antibodies and uses thereof5 Sep 2024US 2024/0293539 A1Icosagen Cell Factory OÜ
Most cited
By later US patents
- Recombinant production of mixtures of antibodies141US 7,262,028 B2Crucell Holland B. V. · 2007
- Production and use of novel peptide-based agents for use with bi-specific antibodies66US 6,962,702 B2Immunomedics, Inc. · 2005
- Recombinant production of mixtures of antibodies61US 7,429,486 B2Crucell Holland B. V. · 2008
- Recombinant production of mixtures of antibodies39US 7,927,834 B2Merus N.V. · 2011
- Recombinant production of mixtures of antibodies38US 7,932,360 B2Merus N.V. · 2011